Alternatives to Acetazolamide (Diamox)
The best alternatives to acetazolamide depend on the specific indication: for glaucoma, use topical dorzolamide or brinzolamide; for acute mountain sickness, use low-flow oxygen or ibuprofen; for central sleep apnea, use low-flow oxygen; for heart failure-related diuresis, use standard loop diuretics; and for idiopathic intracranial hypertension, consider topiramate or GLP-1 receptor agonists.
By Clinical Indication
Glaucoma
Topical carbonic anhydrase inhibitors (dorzolamide 2% or brinzolamide) are the primary alternatives for reducing intraocular pressure 1. While dorzolamide is less effective than systemic acetazolamide—reducing aqueous humor flow by 17% versus 30% and IOP by 13% versus 19%—it avoids systemic side effects 2. When added to dorzolamide, acetazolamide provides additional benefit, but the reverse is not true, indicating dorzolamide reaches a ceiling effect 2.
Key consideration: Topical agents are preferred first-line for chronic glaucoma management due to better tolerability, reserving systemic acetazolamide for refractory cases or acute situations.
Acute Mountain Sickness (AMS)
For AMS prevention, you have two evidence-based alternatives:
Low-flow oxygen is recommended by the 2025 American Academy of Sleep Medicine guidelines for high-altitude CSA, though with very low certainty evidence 3. It acutely reduces AHI/ODI but may not improve subjective sleep quality.
Ibuprofen 600 mg three times daily (starting 4 hours before ascent) showed slightly inferior efficacy to acetazolamide 125 mg twice daily, with AMS incidence of 62.2% versus 51.1%, exceeding the noninferiority margin 4. However, symptom severity was similar between groups. Ibuprofen should not be recommended over acetazolamide for rapid ascent but may serve as an alternative when acetazolamide is contraindicated 4.
Clinical pearl: Acetazolamide remains superior for AMS prevention, with the extended-release 500 mg once-daily formulation showing 36.9% versus 55.9% AMS incidence compared to placebo in Asian populations 5.
Central Sleep Apnea (CSA)
Low-flow oxygen is the primary alternative for CSA, particularly in heart failure patients 3. The 2025 AASM guideline provides a low certainty recommendation favoring oxygen for CSA in heart failure, noting it's clinically relevant though not universally covered by insurance 3.
Important caveat: For high-altitude CSA, both oxygen and acetazolamide show very low certainty evidence. Many individuals acclimate naturally, and definitive treatment is descent 3. CSA at altitude doesn't require intervention unless symptomatic.
Heart Failure and Diuresis
Standard loop diuretics remain the cornerstone of heart failure management. While acetazolamide shows improved diuretic efficiency and natriuresis (mean difference 56.98 mmol, 95% CI 27.7-86.2) when added to loop diuretics 6, it's used as adjunctive therapy rather than replacement 7.
Critical insight: Neither acetazolamide nor SGLT2 inhibitors produce sustained natriuresis due to compensatory distal nephron sodium reabsorption 7. The clinical benefits of SGLT2 inhibitors in heart failure appear independent of diuretic effects and likely relate to neurohormonal mechanisms 7.
Idiopathic Intracranial Hypertension (IIH)
Emerging alternatives include:
- Topiramate (also an antiepileptic with carbonic anhydrase inhibition)
- GLP-1 receptor agonists (addressing weight-related pathophysiology)
- 11β-HSD1 inhibitors (investigational)
These show promise as adjuncts or alternatives but require further investigation 8.
Epilepsy
Other antiepileptic drugs are preferred based on seizure type and patient factors. Topiramate and zonisamide also possess carbonic anhydrase inhibitory activity 9.
Safety Considerations
Acetazolamide has extensive drug interactions with NSAIDs, other diuretics, antiepileptics, immunosuppressants, anticholinesterase drugs, β-blockers, anesthetics, oral contraceptives, anticancer agents, antifungals, lithium, metformin, and clopidogrel 9. Dosage adjustments are essential when combining with these agents to avoid toxicity.
For heart failure patients with CSA: If using acetazolamide as replacement or additional diuretic, monitor electrolytes after 2-4 weeks due to concerns about acid-base disturbance and arrhythmia risk in hyperventilating patients 3. Also assess AHI, sleep quality, and cardiac function.
Practical Algorithm
- Identify the primary indication (glaucoma, AMS, CSA, heart failure, IIH, epilepsy)
- For glaucoma: Start topical dorzolamide/brinzolamide; escalate to systemic acetazolamide if inadequate
- For AMS prevention: Use acetazolamide as first-line; consider ibuprofen only if contraindications exist
- For CSA: Trial low-flow oxygen first, especially in heart failure
- For heart failure diuresis: Optimize loop diuretics before adding acetazolamide
- For IIH: Consider topiramate or GLP-1 agonists, particularly in obese patients
- Check for drug interactions before prescribing any alternative